Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026

From DX Today | No-Hype Podcast About AI & DX Rick Spair

Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026 The Danish drugmaker behind Ozempic and Wegovy is integrating OpenAI's models across drug discovery, clinical trials, manufacturing, supply chain, and commercial operations, with pilots in twenty twenty six and full integration by year end. Rick Spair and Laura unpack what is real, what is theater, and what the deal signals for the rest of regulated industry. Hosted by Rick Spair...